A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02886897 |
|
Recruitment Status : Unknown
Verified August 2016 by Jianchuan Xia, Sun Yat-sen University.
Recruitment status was: Recruiting
First Posted : September 1, 2016
Last Update Posted : September 1, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background: Combinations of dendritic and cytokine-induced killer cell (D-CIK) based adoptive immunotherapy and anti-PD-1 antibody may enhance the immune response and stop cancer cells from growing.
Objective: Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and anti-PD-1 antibody in patients with treatment-refractory solid tumors.
Methodology: Phase II clinical trial in patients with advanced metastatic hepatocellular carcinoma, renal cell carcinoma,bladder cancer,colorectal cancer,non-small-cell lung cancer,breast cancer and other solid cancers. The D-CIK was isolated from peripheral blood of participants,then activated,expanded and incubated with anti-PD-1 antibody before infusion. The enough number (1.0-1.5 *10^10 cells) of D-CIK were infused back into participants.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hepatocellular Carcinoma Renal Cell Carcinoma Bladder Cancer Colorectal Cancer Non-small-cell Lung Cancer Breast Cancer | Biological: D-CIK and anti-PD-1 antibody | Phase 1 Phase 2 |
Heparinized peripheral blood was obtained from participants over a 2-week period. PBMCs were separated by Ficoll-Hypaque gradient centrifugation, suspended in X-VIVO 15 serum-free medium, and culture with 1000 U/ml rhIFN-γfor the first 24 h, followed by stimulation with 100 ng/ml OKT3 , 1000 U/ml rhIL-2 and 100 U/ml IL-1α to activate the CIK.Dendritic cells were incubated with CIK. Fresh medium containing 1000 U/ml rhIL-2 was added every 2 days and the cell density was maintained at 2×10^6 cells/mL.D-CIK were harvested, washed, and resuspended after culture for 14 days. Before cell transfer,D-CIK were incubated with anti-PD-1 antibody,and a fraction of the D-CIK were collected to assess their number, phenotype, and viability of cells, and to test for possible contamination by bacteria, fungi, or endotoxins. Then, autologous D-CIK (1.0-1.5*10^10 cells) were transferred to patients via intravenous infusion. Generally, participants received at least 4 cycles of treatment at 2-week intervals or received doses until disease progression occurred. If the participants were disease-stable, additional cycles of maintenance treatment were eligible.
Participants will be evaluated for the safety, clinical activity and toxicity. The primary end point was the objective response for each participant at the time of D-CIK and anti-PD-1 infusion as assessed by RECIST. Peripheral blood of patients were also assessed for related cytokine using ELISPOT assays. Additional,the investigators will evaluate tumor markers in participants with clinical response/non-response by immunohistochemical staining of tumor sections from previous diagnostic or therapeutic biopsy samples to determine the predictive biomarker that may be used in future studies.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell （D-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors |
| Study Start Date : | July 2016 |
| Estimated Primary Completion Date : | September 2019 |
| Estimated Study Completion Date : | October 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: D-CIK and anti-PD-1 Immunotherapy
D-CIK was incubated with anti-PD-1 antibody before infused back into participants
|
Biological: D-CIK and anti-PD-1 antibody
Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants. |
- Progress-free survival(PFS) [ Time Frame: 12 Months ]PFS is defined as the time from the combined therapy until objective tumor progression or death.
- Overall survival (OS) [ Time Frame: 12 Months ]OS is defined as the time from the combined therapy until death from any cause
- Laboratory findings [ Time Frame: 6 Months ]The number and secreted cytokines of CD3+ (or CD8+ or CD4+ or CD56+) T cells
- Objective response rate [ Time Frame: 12 Months ]The total number of Complete remission and Partial remission (According to the response criteria in solid tumor(RECIST))
- Severity of adverse events [ Time Frame: 12 Months ]According to National Cancer Institute Common Terminology Criteria for Adverse Events（NCI-CTCAE)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participantswith treatment-refractory advanced hepatocellular carcinoma, renal cell carcinoma,bladder cancer,colorectal cancer,non-small-cell lung cancer,breast cancer and other solid cancers.
- Age 18 to 75 years.
- Willing to sign a durable power of attorney.
- Able to understand and sign the Informed Consent Document.
- Life expectancy of greater than three months.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the preparative regimen.
- Adequate organ function.
-
Serology:
- Seronegative for HIV antibody.
- Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.
-
Hematology:
- WBC (> 3000/mm(3)).
- Platelet count greater than 100,000/mm(3).
- Hemoglobin greater than 8.0 g/dl.
-
Chemistry:
- Serum ALT/AST less or equal to 2.5 times the upper limit of normal.
- Serum creatinine less than or equal to 1.6 mg/dl.
- Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.
Exclusion Criteria:
- Previous treatment with anti-CTLA-4 and anti-PD-1/PD-L1.
- Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
- History of autoimmune disease
- Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
- Concurrent antineoplastic therapies and systemic steroid therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02886897
| Contact: Jian-Chuan Xia, Ph.D. | 862087345699 | xiajch@sysucc.org.cn | |
| Contact: Yi-Xin Zeng, Ph.D. | 862087343333 | zengYX@sysucc.org.cn |
| China, Guangdong | |
| Sun Yat-Sen University, Cancer Center | Recruiting |
| Guangzhou, Guangdong, China, 510060 | |
| Contact: Jian-Chuan Xia, Ph.D. 86-20-87345699 xiajch@sysucc.org.cn | |
| Contact: Fang-jian Zhou, Ph.D. 86-20-87343404 zhoufj@sysucc.org.cn | |
| Principal Investigator: Yi-Xin Zeng, Ph.D. | |
| Sub-Investigator: Jian-Chuan Xia, Ph.D. | |
| Sub-Investigator: Fang-jian Zhou, Ph.D. | |
| Principal Investigator: | Yi-Xin Zeng, Ph.D. | Sun Yat-sen University |
| Responsible Party: | Jianchuan Xia, Director of Biotherapy;Principal Investigator;Professor, Sun Yat-sen University |
| ClinicalTrials.gov Identifier: | NCT02886897 |
| Other Study ID Numbers: |
B2016-036-01 |
| First Posted: | September 1, 2016 Key Record Dates |
| Last Update Posted: | September 1, 2016 |
| Last Verified: | August 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
|
Refractory solid tumors Dendritic and Cytokine-induced killer cell Anti-PD-1 antibody Combination immunotherapy |
|
Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms by Site Urologic Neoplasms Urogenital Neoplasms Kidney Neoplasms Carcinoma Carcinoma, Renal Cell Adenocarcinoma |
Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Urologic Diseases Male Urogenital Diseases Kidney Diseases Antibodies Immunologic Factors Physiological Effects of Drugs |